Alnylam Pharmaceuticals, Inc.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc carries a market capitalization of 31.02B, placing it among publicly traded companies globally. Its enterprise value stands at 29.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Alnylam Pharmaceuticals, Inc's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc has 133.73M shares outstanding.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc trades at a trailing price-to-earnings ratio of 47.10. The price-to-sales ratio is 7.92, and the price-to-book ratio stands at 28.36.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc trades at an EV/EBITDA multiple of 34.48 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.36 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 29.37B versus a market cap of 31.02B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc maintains a current ratio of 3.05, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 93.60, indicating elevated leverage, while an interest coverage ratio of 3.24 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc posted a return on equity (ROE) of 100.70, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 15.96, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.60M in revenue per employee across its workforce of 2,432.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 11.58 indicates how many times Alnylam Pharmaceuticals, Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc recorded an income tax benefit of -6.80M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 645.91M, leaving 652.72M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 22, 2026, Alnylam Pharmaceuticals, Inc's stock has declined approximately 44.23% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc generated 3.88B in revenue and converted that into 652.72M in net income, yielding earnings per share of 4.75. EBITDA reached 851.89M, while operating income came in at 807.65M.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc holds 2.67B in cash and equivalents against 1.02B in total debt, resulting in a net debt position of -563.33M. Total book value stands at 1.09B, with working capital of 2.51B providing operational flexibility.

Alnylam Pharmaceuticals, Inc produced 736.59M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -74.28M in capital expenditures, free cash flow totaled 662.31M - equivalent to 5.00 per share.

Over the twelve months ended June 30, 2026, Alnylam Pharmaceuticals, Inc posted a gross margin of 79.65, reflecting its pricing power and cost economics. The operating margin of 20.81 and net profit margin of 16.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.08, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.98, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Alnylam Pharmaceuticals, Inc shareholders.

As of June 30, 2026, Alnylam Pharmaceuticals, Inc has an Altman Z-Score of 6.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.